Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, 2026-2033 | Advanced Therapies Propel 12.2% CAGR and $2.39 Billion Opportunity

globenewswire.com
CERT Certara is identified as a market participant in the nonclinical pharmacology and toxicology regulatory consulting outsourcing sector. The article does not offer explicit sentiment but implies the company is involved in a market projected for significant growth.

Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, 2026-2033 | Advanced Therapies Propel 12.2% CAGR and $2.39 Billion Opportunity Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Size, Share & Trends Analysis Report by Service, Application, Modality, Therapeutic Area, End Use, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

Global Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market to Reach USD 2.39 Billion by 2033

The global nonclinical pharmacology and toxicology regulatory consulting outsourcing market was valued at an estimated USD 0.965 billion in 2025 and is projected to reach USD 2.39 billion by 2033. The market is expected to expand at a compound annual growth rate of 12.2% from 2026 to 2033, supported by increasing drug discovery and development activity across pharmaceutical and biotechnology companies.

Growing demand for specialized regulatory guidance during preclinical development is a major market driver. Regulatory authorities, including the U.S. FDA and the European Medicines Agency, require comprehensive pharmacology and safety data before clinical trials can begin. As regulatory requirements become more rigorous, drug developers are increasingly outsourcing nonclinical pharmacology and toxicology consulting to access scientific expertise, strengthen submission strategies, identify potential gaps, and reduce development risks.

Market growth is also being influenced by the increasing complexity of biologics and advanced therapies, heightened global regulatory scrutiny, expanding safety mandates, growth in decentralized trials, and the shift toward new approach methodologies (NAMs). These trends are increasing the need for regulatory consultants with specialized knowledge of nonclinical program design, data interpretation, risk assessment, and submission requirements across multiple jurisdictions.

The transition from conventional small-molecule drugs to complex biologics and advanced therapeutic modalities is further accelerating demand. Expanding biopharmaceutical pipelines now include cell and gene therapies, multi-specific antibodies, RNA-based therapeutics, gene-editing platforms, monoclonal antibodies, and therapeutic proteins. These modalities require tailored preclinical evaluation strategies that address distinct safety profiles, mechanisms of action, biodistribution considerations, and regulatory expectations.

Market Report Scope and Segmentation

The global nonclinical pharmacology and toxicology regulatory consulting outsourcing market report analyzes revenue growth at global, regional, and country levels. It also examines industry trends across key sub-segments from 2021 to 2033. The market is segmented by service, application, modality, therapeutic area, end use, and region.

Service Outlook (Revenue, USD Million, 2021-2033)

Application Outlook (Revenue, USD Million, 2021-2033)

Modality Outlook (Revenue, USD Million, 2021-2033)

Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)

End Use Outlook (Revenue, USD Million, 2021-2033)

Regional Outlook (Revenue, USD Million, 2021-2033)

Strategic Value of the Report

The report provides pharmaceutical companies, biotechnology developers, research institutions, investors, and regulatory consulting organizations with market intelligence for evaluating expansion opportunities and competitive positioning. It also highlights the regulatory, scientific, and therapeutic trends expected to shape the nonclinical pharmacology and toxicology regulatory consulting outsourcing market through 2033.

Key Attributes:

Key Topics Covered:

Chapter 1. Research Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Service

1.2.2. Application

1.2.3. Modality

1.2.4. Therapeutic Area

1.2.5. End Use

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased Database

1.4.2. Internal Database

1.4.3. Secondary Sources

1.4.4. Primary Research

1.5. Information Or Data Analysis

1.5.1. Data Analysis Models

1.6. Market Formulation & Validation

1.7. Model Details

1.7.1. Commodity Flow Analysis

1.7.2. Top-Down Analysis

1.7.3. Botton-Up Approach

1.7.4. Multivariate Analysis

1.8. List of Secondary Sources

1.9. List of Abbreviations

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.3. Competitive Insights

Chapter 3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Market Dynamics

3.2.1. Market Driver Analysis

3.2.2. Market Restraint Analysis

3.3. Technological Advancements

3.4. Pricing Model Analysis

3.5. Tariff Impact Analysis

3.6. Value Chain Analysis

3.6.1. Supply Trends

3.6.2. Demand Trends

3.7. Market Analysis Tools

3.7.1. Porter's Five Force Analysis

3.7.2. PESTEL by SWOT Analysis

Chapter 4. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Service Estimates & Trend Analysis

4.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Service: Segment Dashboard

4.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Service: Movement Analysis

4.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, by Service, 2021-2033 (USD Million)

4.4. Regulatory Strategy & Nonclinical Development Planning

4.4.1. Regulatory Strategy & Nonclinical Development Planning Market Estimates and Forecasts, 2021-2033 (USD Million)

4.5. IND / CTA-Enabling Nonclinical Program Design

4.5.1. IND / CTA-Enabling Nonclinical Program Design Market Estimates and Forecasts, 2021-2033 (USD Million)

4.6. Regulatory Gap Analysis & Risk Assessment

4.6.1. Regulatory Gap Analysis & Risk Assessment Market Estimates and Forecasts, 2021-2033 (USD Million)

4.7. Data Interpretation & Regulatory Writing

4.7.1. Data Interpretation & Regulatory Writing Market Estimates and Forecasts, 2021-2033 (USD Million)

4.8. Lifecycle & Post-IND Nonclinical Consulting

4.8.1. Lifecycle & Post-IND Nonclinical Consulting Market Estimates and Forecasts, 2021-2033 (USD Million)

4.9. Others

4.9.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 5. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Application Estimates & Trend Analysis

5.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Application: Segment Dashboard

5.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Application: Movement Analysis

5.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, by Application, 2021-2033 (USD Million)

5.4. Pre-IND Stage

5.4.1. Pre-IND Stage Market Estimates and Forecasts, 2021-2033 (USD Million)

5.5. IND / CTA Submission Support

5.5.1. IND / CTA Submission Support Market Estimates and Forecasts, 2021-2033 (USD Million)

5.6. BLA / MAA

5.6.1. BLA / MAA Market Estimates and Forecasts, 2021-2033 (USD Million)

5.7. Others

5.7.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 6. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Modality Estimates & Trend Analysis

6.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Modality: Segment Dashboard

6.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Modality: Movement Analysis

6.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, by Modality, 2021-2033

6.4. Small Molecules

6.4.1. Small Molecules Market Estimates and Forecasts, 2021-2033 (USD Million)

6.5. Biologics

6.5.1. Biologics Market Estimates and Forecasts, 2021-2033 (USD Million)

6.6. Cell and Gene Therapies

6.6.1. Cell and Gene Therapies Market Estimates and Forecasts, 2021-2033 (USD Million)

6.7. Others

6.7.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 7. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Therapeutic Area Estimates & Trend Analysis

7.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Therapeutic Area: Segment Dashboard

7.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by Therapeutic Area: Movement Analysis

7.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, by Therapeutic Area, 2021-2033 (USD Million)

7.4. Oncology

7.4.1. Oncology Market Estimates and Forecasts, 2021-2033 (USD Million)

7.5. Autoimmune & Inflammatory Diseases

7.5.1. Autoimmune & Inflammatory Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)

7.6. CNS

7.6.1. CNS Market Estimates and Forecasts, 2021-2033 (USD Million)

7.7. Cardiovascular & Metabolic

7.7.1. Cardiovascular & Metabolic Market Estimates and Forecasts, 2021-2033 (USD Million)

7.8. Infectious Diseases

7.8.1. Infectious Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)

7.9. Rare Diseases

7.9.1. Rare Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)

7.10. Others

7.10.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 8. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: End Use Estimates & Trend Analysis

8.1. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by End Use: Segment Dashboard

8.2. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market, by End Use: Movement Analysis

8.3. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market Estimates & Forecasts, by End Use, 2021-2033 (USD Million)

8.4. Pharmaceutical and Biopharmaceutical Companies

8.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021-2033 (USD Million)

8.5. Academic and Research Institutes

8.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021-2033 (USD Million)

8.6. Others

8.6.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)

Chapter 9. Nonclinical Pharmacology and Toxicology Regulatory Consulting Outsourcing Market: Regional Estimates & Trend Analysis

9.1. Regional Market Share Analysis, 2025 & 2030

9.2. Regional Market Dashboard

9.3. Global Regional Market Snapshot

9.4. North America

9.4.1. North America Market Estimates and Forecasts, 2021-2033 (USD Million)

9.4.2. U.S

9.4.3. Canada

9.4.4. Mexico

9.5. Europe

9.5.1. Europe Market Estimates and Forecasts, 2021-2033 (USD Million)

9.5.2. UK

9.5.3. Germany

9.5.4. France

9.5.5. Italy

9.5.6. Spain

9.5.7. Denmark

9.5.8. Sweden

9.5.9. Norway

9.6. Asia-Pacific

9.6.1. Asia-Pacific Market Estimates and Forecasts, 2021-2033 (USD Million)

9.6.2. Japan

9.6.3. China

9.6.4. India

9.6.5. Thailand

9.6.6. South Korea

9.6.7. Australia

9.7. Latin America

9.7.1. Latin America Market Estimates and Forecasts, 2021-2033 (USD Million)

9.7.2. Brazil

9.7.3. Argentina

9.8. MEA

9.8.1. MEA Market Estimates and Forecasts, 2021-2033 (USD Million)

9.8.2. South Africa

9.8.3. Saudi Arabia

9.8.4. UAE

9.8.5. Kuwait

9.8.6. Oman

9.8.7. Qatar

Chapter 10. Competitive Landscape

10.1. Market Participant Categorization

10.2. Market Assessment Analysis, 2025 (Heat Map Analysis)

10.3. Company Profiles

10.3.1. Parexel International (MA) Corporation

10.3.2. ToxStrategies

10.3.3. Certara

10.3.4. Dark Horse Consulting Group

10.3.5. ELIQUENT Life Sciences

10.3.6. SciLucent

10.3.7. Latham BioPharm Group (Sia Partners)

10.3.8. Salamandra

10.3.9. Akkeri Inc.

10.3.10. Aclairo Pharmaceutical Development Group, Inc.

10.3.11. Biologics Consulting Group, Inc.

List of Tables [162]

List of Figures [111]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/l0mq62

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.